Locally advanced mismatch repair-deficient gastroesophageal junction cancer: Diagnosis, treatment modifications, and monitoring

Abstract

Rutika Mehta has served on advisory boards for Bristol-Myers Squibb Company, Eli Lilly & Company, Merck, Astellas Pharma US Inc., Novartis, BostonGene, Guardant Health, SeaGen Inc., and Natera; and on a Data and Safety Monitoring Board for Arcus Biosciences outside the submitted work. Christine Walko is employed by Mission Healthcare, has stock and ownership interests in Nabriva Therapeutics, and has served on advisory boards or as a consultant for Jackson Laboratory for Genomic Medicine, Intermountain Precision Genomics, and Clarified Precision Medicine outside the submitted work. Laura Barton reports consulting fees from AstraZeneca outside the submitted work. Gregory Lauwers reports consulting fees from ALIMENTIV outside the submitted work. The remaining authors disclosed no conflicts of interest.